Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Two New Reports Highlight Stalled Progress Against Diarrheal Disease: Nearly 1.6m Children Die Each Year From These Preventable And Treatable Diseases
PATH and WaterAid America released two new reports that show that the international aid community and developing-country governments are not responding to clear evidence on child mortality by targeting res where the disease burden is greatest. Diarrheal disease, a leading killer of children under age five worldwide, is responsible for the deaths of nearly 1.6 million children annually, yet it receives very little attention from both policymakers and the public. During the 1980s and 1990s, diarrheal disease mortality rates were cut by nearly 50 percent, made possible by wide availability and implementation of lifesaving prevention and treatment interventions.
generic viagra online
Chair Of General Pharmaceutical Council Is Welcomed By Society
The Royal Pharmaceutical Society of Great Britain (RPSGB) has welcomed the appointment of Mr Robert Nicholls CBE as the Chair Designate of the General Pharmaceutical Council (GPhC).
News of the day
Cardium Presents Gene Activated Matrix Technology And Update On Excellarate Clinical Development Program At ASGT Annual Meeting
Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) announced a presentation entitled "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic Ulcers" at the Late Stage Industry Clinical Trials Symposium at the American Society of Gene Therapy (ASGT) Annual meeting in San Diego, California, on May 27, 2009. Dr. Barbara K. Sosnowski, Cardium"s Vice President of Biologics Development and the Chief Operating Officer of Cardium"s Tissue Repair Company Operating Unit, provided an update on TRC"s Phase 2b MATRIX clinical trial and the new formulation of the Excellarate(TM) product candidate, as well as an overview of the prior clinical study of Excellarate.
Diagnostics

WHO Reviews Antiretroviral Recommendations For Pregnant, Breastfeeding Women With HIV

The World Health Organization is reviewing its 2006 guidelines on the use of antiretroviral drugs by HIV-positive pregnant and breastfeeding women because of new evidence that prolonged use can cut the risk of mother-to-child transmission, Reuters reports. Current guidelines recommend that these women receive a short-course antiretroviral regimen. However, a new study released at an international AIDS conference on Wednesday shows that a stronger regimen over a prolonged period significantly lowers the risk of mother-to-child transmission.The study examined 824 pregnant women in Burkina Faso, Kenya and South Africa who received either the standard antiretroviral regimen or a combination of three antiretrovirals. The combination regimen was administered during the last trimester and for a maximum of six months during breastfeeding, according to study leader Tim Farley of WHO"s Department of Reproductive Health. Farley said women who received the combination regimen during pregnancy, delivery and breastfeeding had a 42% lower risk of transmitting HIV to their infants than women given the standard course.Farley added, "The results of this study show an almost twofold reduction in the risk of HIV transmission during the breastfeeding period and also [show] there is no short-term toxicity" to the women or their infants. He said that participants will be monitored for any long-term health effects. WHO is expected to release the updated recommendations by the end of the year (Roelf, Reuters, 7/21). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009